JP2023526754A5 - - Google Patents
Info
- Publication number
- JP2023526754A5 JP2023526754A5 JP2022563894A JP2022563894A JP2023526754A5 JP 2023526754 A5 JP2023526754 A5 JP 2023526754A5 JP 2022563894 A JP2022563894 A JP 2022563894A JP 2022563894 A JP2022563894 A JP 2022563894A JP 2023526754 A5 JP2023526754 A5 JP 2023526754A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- atazanavir
- cycloprolylglycine
- artemether
- twice daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063012432P | 2020-04-20 | 2020-04-20 | |
| US63/012,432 | 2020-04-20 | ||
| US202063018768P | 2020-05-01 | 2020-05-01 | |
| US63/018,768 | 2020-05-01 | ||
| US202063032116P | 2020-05-29 | 2020-05-29 | |
| US63/032,116 | 2020-05-29 | ||
| US202063037373P | 2020-06-10 | 2020-06-10 | |
| US63/037,373 | 2020-06-10 | ||
| US202063041812P | 2020-06-19 | 2020-06-19 | |
| US63/041,812 | 2020-06-19 | ||
| US202163170350P | 2021-04-02 | 2021-04-02 | |
| US63/170,350 | 2021-04-02 | ||
| PCT/US2021/027848 WO2021216385A1 (en) | 2020-04-20 | 2021-04-17 | Methods for the prophylaxis and treatment of covid and covid-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526754A JP2023526754A (ja) | 2023-06-23 |
| JP2023526754A5 true JP2023526754A5 (enExample) | 2024-04-30 |
Family
ID=78270185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563894A Pending JP2023526754A (ja) | 2020-04-20 | 2021-04-17 | Ｃｏｖｉｄ および ｃｏｖｉｄ－１９ の予防と治療の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12239629B2 (enExample) |
| EP (1) | EP4138906A4 (enExample) |
| JP (1) | JP2023526754A (enExample) |
| AU (1) | AU2021259185A1 (enExample) |
| BR (1) | BR112022021304A2 (enExample) |
| CA (1) | CA3179317A1 (enExample) |
| GB (3) | GB2632086A (enExample) |
| WO (1) | WO2021216385A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179317A1 (en) * | 2020-04-20 | 2021-10-28 | Lloyd Hung Loi TRAN | Methods for the prophylaxis and treatment of covid and covid-19 |
| BR112022022243A2 (pt) * | 2020-05-01 | 2022-12-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19. |
| CN118354775A (zh) * | 2021-10-06 | 2024-07-16 | 麦蒂恩斯株式会社 | 包含依法韦仑及氟西汀作为有效成分的用于预防或治疗病毒感染疾病的药物组合物 |
| AU2022382676B2 (en) * | 2021-11-05 | 2026-04-02 | G2Gbio, Inc. | Pharmaceutical kit for parenteral co-administration |
| WO2023086547A1 (en) * | 2021-11-12 | 2023-05-19 | Albert Einstein College Of Medicine | Cell impermeable kinase inhibitors to treat sars-cov-2 and/or hsv viral infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002340465A1 (en) | 2001-11-09 | 2003-05-19 | Neuronz Biosciences, Inc. | Cyclo(prolyl-glycine) and methods of use to treat neural disorders |
| US7232798B2 (en) | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| PL2139515T5 (pl) | 2007-03-30 | 2024-04-08 | The Research Foundation Of The State University Of New York | Atenuowane wirusy przydatne w szczepionkach |
| WO2009023059A2 (en) * | 2007-06-01 | 2009-02-19 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
| MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
| US10980756B1 (en) * | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| HUE064089T2 (hu) * | 2020-04-16 | 2024-02-28 | Mereo Biopharma 4 Ltd | Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére |
| CA3179317A1 (en) * | 2020-04-20 | 2021-10-28 | Lloyd Hung Loi TRAN | Methods for the prophylaxis and treatment of covid and covid-19 |
| CN111803491A (zh) * | 2020-07-24 | 2020-10-23 | 中国人民解放军军事科学院军事医学研究院 | 青蒿素类化合物在治疗冠状病毒感染方面的应用 |
| CN114246858A (zh) * | 2020-09-21 | 2022-03-29 | 北京化工大学 | 青蒿素类化合物在治疗和预防冠状病毒感染中的应用 |
-
2021
- 2021-04-17 CA CA3179317A patent/CA3179317A1/en not_active Abandoned
- 2021-04-17 GB GB2416046.7A patent/GB2632086A/en active Pending
- 2021-04-17 BR BR112022021304A patent/BR112022021304A2/pt not_active Application Discontinuation
- 2021-04-17 JP JP2022563894A patent/JP2023526754A/ja active Pending
- 2021-04-17 GB GB2217355.3A patent/GB2613460B/en active Active
- 2021-04-17 WO PCT/US2021/027848 patent/WO2021216385A1/en not_active Ceased
- 2021-04-17 AU AU2021259185A patent/AU2021259185A1/en not_active Abandoned
- 2021-04-17 EP EP21793162.5A patent/EP4138906A4/en active Pending
-
2022
- 2022-10-18 US US18/047,432 patent/US12239629B2/en active Active
-
2024
- 2024-11-01 GB GB2416189.5A patent/GB2644651A/en active Pending
-
2025
- 2025-01-25 US US19/037,137 patent/US20250319060A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| US20080096832A1 (en) | Method for Improving the Pharmacokinetics of an NNRTI | |
| GB2613460A (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| JP2006506378A5 (enExample) | ||
| JP2017510607A5 (enExample) | ||
| ZA202201465B (en) | Long-lasting formulation containing rivastigmine, and method for preparing same | |
| JP2018502168A5 (enExample) | ||
| DK166479B (da) | Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JP2016505050A5 (enExample) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2023523373A5 (enExample) | ||
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| KR20100124860A (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| JPH05201861A (ja) | デキストロメトルフアンの鎮咳効果の増強 | |
| JP2023539847A5 (enExample) | ||
| JP2023554354A5 (enExample) | ||
| JP2006508993A5 (enExample) | ||
| JPS62267227A (ja) | 血中尿酸濃度の低下用医薬 | |
| US20070244102A1 (en) | Combination of Dermaciclane and Opoids as Analgesics | |
| IL312456A (en) | Treatment of major depressive disorder | |
| JP2018177773A (ja) | 医薬 | |
| JPH0848639A (ja) | 改善された血圧上昇薬 |